TY - JOUR
T1 - Toxicological considerations when creating nanoparticle-based drugs and drug delivery systems
AU - Sharma, Arati
AU - Madhunapantula, Subbarao V.
AU - Robertson, Gavin P.
N1 - Funding Information:
GP Robertson has received financial support from the National Institutes of Health (NIH CA-136667-02, NIH CA-1138634-02) as well as support from the Foreman Foundation for Melanoma Research. A Sharma has received support from the National Institutes of Health (NIH CA-142060-02, and the Bassumian Trust, PA. S Madhunapantula declares that he has no conflict of interest and has recieved no payment in the preparation of this manuscript.
PY - 2012/1
Y1 - 2012/1
N2 - Introduction: The biggest challenge faced by the scientific community involved in drug development is to deliver safe and effective dosage of drugs without causing systemic toxicity. Therefore, novel nano-based delivery vehicles specifically targeting tumors but not normal tissues are urgently needed. Areas covered: Nanoparticles have beneficial aspects but can be toxic themselves, which is always a concern for any drug or delivery agent. This review examines and details the toxicological aspects that should be considered when planning to use nanoparticles in animals or in man for drug delivery or imaging. Subjects discussed in this review include i) overviews of applications of various nanoparticles for drug delivery and imaging; ii) toxicological aspects to consider when selecting particular nanoparticles for use in various applications in animals or man; iii) hurdles faced when examining nanoparticle toxicity; and iv) current approaches for assessing nanoparticle toxicity. Expert opinion: Nanotechnology has significant potential for advancing therapeutic efficacy and imaging in cancer; however, these agents can be toxic. Therefore, toxicity needs to be considered when selecting nanoparticles for a particular application. Methods for assessing nanoparticle toxicity need to be improved and standardized across all nanotechnology platforms in order to speed up the application of nanoparticle use in humans.
AB - Introduction: The biggest challenge faced by the scientific community involved in drug development is to deliver safe and effective dosage of drugs without causing systemic toxicity. Therefore, novel nano-based delivery vehicles specifically targeting tumors but not normal tissues are urgently needed. Areas covered: Nanoparticles have beneficial aspects but can be toxic themselves, which is always a concern for any drug or delivery agent. This review examines and details the toxicological aspects that should be considered when planning to use nanoparticles in animals or in man for drug delivery or imaging. Subjects discussed in this review include i) overviews of applications of various nanoparticles for drug delivery and imaging; ii) toxicological aspects to consider when selecting particular nanoparticles for use in various applications in animals or man; iii) hurdles faced when examining nanoparticle toxicity; and iv) current approaches for assessing nanoparticle toxicity. Expert opinion: Nanotechnology has significant potential for advancing therapeutic efficacy and imaging in cancer; however, these agents can be toxic. Therefore, toxicity needs to be considered when selecting nanoparticles for a particular application. Methods for assessing nanoparticle toxicity need to be improved and standardized across all nanotechnology platforms in order to speed up the application of nanoparticle use in humans.
UR - http://www.scopus.com/inward/record.url?scp=84255182571&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84255182571&partnerID=8YFLogxK
U2 - 10.1517/17425255.2012.637916
DO - 10.1517/17425255.2012.637916
M3 - Review article
C2 - 22097965
AN - SCOPUS:84255182571
SN - 1742-5255
VL - 8
SP - 47
EP - 69
JO - Expert Opinion on Drug Metabolism and Toxicology
JF - Expert Opinion on Drug Metabolism and Toxicology
IS - 1
ER -